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Abstract
Background: Astrocyte elevated gene-1 (AEG-1) is associated with tumorigenesis and progression in diverse
human cancers. The present study was aimed to investigate the clinical and prognostic significance of AEG-1 in
salivary gland carcinomas (SGC).
Methods: Real-time PCR and western blot analyses were employed to examine AEG-1 expression in two normal
salivary gland tissues, eight SGC tissues of various clinical stages, and five pairs of primary SGC and adjacent salivary
gland tissues from the same patient. Immunohistochemistry (IHC) was performed to examine AEG-1 protein
expression in paraffin-embedded tissues from 141 SGC patients. Statistical analyses was applies to evaluate the
diagnostic value and associations of AEG-1 expression with clinical parameters.
Results: AEG-1 expression was evidently up-regulated in SGC tissues compared with that in the normal salivary
gland tissues and in matched adjacent salivary gland tissues. AEG-1 protein level was positively correlated with
clinical stage (P < 0.001), T classification (P = 0.008), N classification (P = 0.008) and M classifications (P = 0.006).
Patients with higher AEG-1 expression had shorter overall survival time, whereas those with lower tumor AEG-1
expression had longer survival time.
Conclusions: Our results suggest that AEG-1 expression is associated with SGC progression and may represent a
novel and valuable predictor for prognostic evaluation of SGC patients.
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Background
Salivary gland carcinoma (SGC) is a relatively rare can-
cer that accounts for less than 5% of all head and neck
cancers [1,2]. It is among the most complex malignan-
cies owing to diverse histological characteristics and bio-
logical behaviors. According to the World Health
Organization (WHO) classification, SGC is one of the
most complex malignancies for it has up to 24 different
histological subtypes [3]. Although there have been
some remarkable advances, treating SGC is still challen-
ging, and the clinical outcomes of advanced SGC have
not significantly improved [4]. More than 5% of patients
suffer a recurrence at the primary site and/or distant
metastasis, and the incidence of occult lymph node
metastasis is also high in major SGC types [5,6]. Due to
the limited number of cases available in most series of
salivary gland tumors, the molecular mechanism of the
development and progression of SGC is still poorly
understood. Therefore, it is of great value to better
understand the etiology and to identify valuable diagnos-
tic and prognostic markers as well as novel therapeutic
strategies of the disease.
AEG-1 was originally discovered as a novel protein
induced by HIV-1 or tumor necrosis factor-a in primary
human fetal astrocytes [7-9]. In recent years, numerous
researches have revealed the essential role of AEG-1 in
the development and progression of cancer. Aberrant
elevation of AEG-1 expression frequently occurs in
human cancers, including breast cancer, glioma, mela-
noma, esophageal squamous cell carcinoma, prostate
cancer, hepatocellular carcinoma and gastric cancer
[10-16]. As a downstream target of Ha-Ras, AEG-1 has
an essential role in regulating tumorigenesis, invasion,
metastasis and angiogenesis [17]. AEG-1 can promote
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independent cell growth and suppress apoptosis through
activation of PI3K-Akt signaling [18-21], and increase
anchorage-independent growth of non-tumorigenic
astrocytes through activation of PI3K-Akt and NF-B
pathway [18,22]. In addition, knockdown of AEG-1
inhibits the progression of prostate cancer through up-
regulation of FOXO3a activity [15]. Moreover, overex-
pression of AEG-1 promotes tumorigenesis and progres-
sion via activation of the Wnt/b-Catenin and NF-B
pathways in hepatocellular carcinoma [11]. Further
more, AEG-1 can regulate human malignant glioma
invasion through up-regulation of matrix metalloprotei-
nase-9 and activating the NF-B signaling pathway
[10,19,22,23]. These findings suggest that AEG-1 plays a
dominant positive role in development and progression
of diverse cancers.
However, whether AEG-1 deregulation also occurs in
SGC remains unclear. To address this question, we
investigated the expression of AEG-1 in SGC and evalu-
ate its prognostic significance by correlating AEG-1
expression levels with clinicopathologic features and
survival in 141 archived SGC samples.
Methods
Patients and tissue specimens
Paraffin-embedded, archived SGC samples were
obtained from 141 patients diagnosed with SGC
between January 2001 and December 2003 at the Sun
Yat-sen University Cancer Center. Clinical and patholo-
gic classification and staging were determined according
to the classification criteria proposed by the WHO [3].
Clinical information for the samples is summarized in
Table 1. Two normal salivary gland tissues obtained
from patients with head and neck tumors undergoing
surgical procedures, eight biopsies of SGC tissues and
five pair of SGC tissues with matched adjacent non-can-
cerous salivary gland tissuesw e r ef r o z e na n ds t o r e di n
liquid nitrogen until further use. For the use of these
clinical materials for research purposes, prior patient
consent and approval from the Institutional Research
Ethics Committee were obtained.
RNA extraction and real-time PCR
Total RNA from tissue samples were extracted using the
Trizol reagent (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instruction. Real-time PCR was per-
formed according to standard methods as described pre-
viously [24]. Sequences of the real-time PCR primers
and probes have been reported previously [13]. Expres-
sion data were normalized to the geometric mean of
the housekeeping gene GAPDH [13] and calculated as
2
-[(Ct of AEG-1)-(Ct of GAPDH)],w h e r eC t represents the
threshold cycle for each transcript.
Western blot
Western blots were performed according to standard
methods as described previously [13], using a rabbit
anti-AEG-1 polyclonal antibody (1:500; Zymed). A
mouse anti-a-Tubulin antibody (1:1,000; Sigma, Saint
Louis, MI) was used as an inner control.
Immunohistochemical (IHC) analysis
IHC analysis were carried out similarly to previously
described methods [13]. Briefly, tissue sections were
incubated with a rabbit anti-AEG-1 antibody (1:200;
Zymed) overnight at 4°C. For negative controls, the rab-
bit anti-AEG-1 antibody was replaced with normal non-
immune serum.
T h ed e g r e eo fIo fp a r a f f i n - e m b e d d e ds e c t i o n sw a s
reviewed and scored independently by two observers,
based on both the proportion of positively stained
tumor cells and the intensity of staining [13]. The pro-
portion of tumor cells was scored as follows: 0 (no posi-
tive tumor cells), 1 (< 10% positive tumor cells), 2 (10-
50% positive tumor cells) and 3 (> 50% positive tumor
cells). The intensity of staining was graded according to
Table 1 Clinicopathological characteristics of patient
samples and expression of AEG-1 in salivary gland cancer
All cases
(%)
All cases
(%)
Gender Histological Types
Male 77 (54.61) Mucoepidermoid
carcinoma
34 (24.11)
Female 64 (45.39) Adenoid cystic carcinoma 20 (14.18)
Age (years) Acinar cell carcinoma 21 (14.89)
< 48 72 (51.06) Adenocarcinoma 23 (16.31)
≥ 48 69 (48.94) Squamous cell carcinoma 12 (8.51)
Clinical Stage Salivary duct carcinoma 16 (11.35)
I 16 (11.35) Basal cell carcinoma 15 (10.64)
II 49 (34.75) Vital status (at follow-
up)
III 34 (24.11) Alive 95 (67.38)
IV 42 (29.79) Death (all SGC-related) 46 (32.62)
T
classification
Expression of AEG-1
T1 17 (12.06) Negative 5 (3.55)
T2 60 (42.55) Positive 136 (96.45)
T3 33 (23.40) Low expression 62 (43.97)
T4 31 (21.99) High expression 79 (56.03)
N
classification
Drinking
N0 106 (75.18) No 117 (82.98)
N1 17 (12.06) Yes 24 (17.02)
N2 18 (12.77) Smoking
M
classification
No 101 (71.63)
No 99 (70.21) Yes 40 (28.37)
Yes 42 (29.79)
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light yellow), 2 (moderate staining = yellow brown) and
3 (strong staining = brown). The staining index (SI) was
calculated as staining intensity score × proportion of
positive tumor cells. Using this method of assessment,
we evaluated the expression of AEG-1 in benign salivary
gland tissues and SGC lesions by determining the SI,
w h i c hs c o r e sa s0 ,1 ,2 ,3 ,4 ,6a n d9 .C u t o f fv a l u e sf o r
AEG-1 were chosen on the basis of a measure of hetero-
geneity with the log-rank test statistical analysis with
respect to overall survival. An optimal cutoff value was
identified: the SI score of ≥ 4 was used to define tumors
as having high AEG-1 expression and ≤ 3a sh a v i n gl o w
expression of AEG-1.
To account for inconsistencies in IHC stain intensities,
the mean optical density (MOD) method, which was
used for the scoring of the staining intensity, was
applied in the current study. In brief, the stained slides
were evaluated at 200× magnification using the SAMBA
4000 computerized image analysis system with Immuno
4.0 quantitative program (Image Products International,
Chantilly, VA). Ten representative staining fields of each
tumor sample were analyzed to determine the MOD,
which represented the concentration of the stain or pro-
portion of positive pixels within the whole tissue. A
negative control for each staining batch was used for
background subtraction in the quantitative analysis. The
data were statistically analyzed using t-test to determine
the differences in average MOD values between different
groups of tissues. P < 0.05 was considered significant.
Statistical analyses
All statistical analyses were carried out using the SPSS
13.0 statistical software package. Comparisons between
groups for statistical significance were performed with a
two-tailed paired Student’s t test. The chi-square test
was used to analyze the relationship between AEG-1
expression and clinicopathologic features. Bivariate cor-
relations between variables were calculated by Spear-
man’s correlation coefficients. Survival curves were
plotted by the Kaplan-Meier method and compared
using the log-rank test. Survival data were evaluated
using univariate and multivariate Cox regression ana-
lyses. P < 0.05 in all cases was considered statistically
significant.
Results
AEG-1 is up-regulated in SGC
Western blot analysis revealed that AEG-1 protein was
barely detectable in the two normal salivary gland tis-
sues, whereas it was strongly expressed in all eight SGC
biopsy tissues (Figure 1A). Real-time PCR was per-
formed to test the mRNA levels of these samples. In
consistent with the up-regulated protein levels, all eight
SGC tissues exhibited significantly higher levels of AEG-
1 mRNA compared with that of the normal salivary
gland tissues (Figure 1B).
Further comparative analysis was done in the five
pairs of primary SGC tissues and their matched adjacent
non-cancerous tissues by Western blot and real-time
PCR analysis. The results revealed that the expression
level of AEG-1 protein was significantly up-regulated in
all five of the SGC tumors (Figure 1C). By real-time
PCR analysis, the tumor/adjacent non-cancerous (T/N)
ratio of AEG-1 mRNA expression was > 2-fold in all
these samples, and the highest ratio was up to about 8-
fold (Figure 1D). In the mean time, the expression of
the AEG-1 protein was also found to be up-regulated in
all 5 human primary SGC tissue samples as compared
to the expression in their matched adjacent noncancer-
ous tissues by IHC analyses (Figure 1E).
Overexpression of AEG-1 protein in archived SGC samples
To determine the role of AEG-1 in the clinical progres-
sion of SGC, IHC analysis was performed in 141 paraf-
fin-embedded, archived SGC tissue samples, including
nine histological types of SGC: mucoepidermoid carci-
noma, adenoid cystic carcinoma, acinar cell carcinoma,
adenocarcinoma, squamous cell carcinoma, salivary duct
carcinoma and basal cell carcinoma. AEG-1 protein was
positively detected in 96.5% (136/141) of the SGC sam-
ples (Table 1) and mainly localized in the cytoplasm of
primary cancer cells, which was in consistent with pre-
vious reports on AEG-1 expression in other cancer
types [10,12,13,25]. As shown in Figure 2A and 2B, the
expression of AEG-1 was up-regulated in all the exam-
ined histological types of SGC compared with their adja-
cent normal tissues.
Figure 2B shows representative IHC stained tumor
sections of each of the four WHO grades of SGC. Mod-
erate to strong cytoplasmic staining of AEG-1 protein
was observed in tumor cells in these primary SGC tis-
sues. By contrast, weak or negative signals were
observed in control normal tissues (Figure 2B). Quanti-
tative IHC analysis revealed that the MOD values of
AEG-1 staining in all primary SGC were higher than
that in control normal tissues and increased along with
the progression of tumor grades I to IV (P < 0.001,
Figure 2C).
Increased AEG-1 expression correlates with
clinicopathologic features of SGC
We further examined the possible correlations between
expression levels of AEG-1 and clinical features of SGC.
As summarized in Table 2 analyzing of 141 primary
SGC samples indicated that AEG-1 expression was
strongly correlated with clinical stage (P =0 . 0 0 1 ) ,
T classification (P = 0.008), N classification (P = 0.008)
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Page 3 of 10and distant metastasis (P = 0.006). Spearman correlation
analysis (Table 3) proved that high AEG-1 expression
level was strongly correlated with advanced clinical
stage (R = 0.283, P = 0.001), advanced T classification
(R = 0.226, P = 0.007), lymph node involvement (R =
0.222, P = 0.008), and distant metastasis (R = 0.232, P =
0.005). However, our analyses did not show significant
associations between AEG-1 expression and other clini-
cal features including age, gender, histological type, his-
tory of drinking and smoking.
Figure 1 Upregulation of AEG-1 expression in SGC tissues. (A and B) Expression of AEG-1 protein and mRNA in 2 normal human salivary
gland tissues and 8 SGC tissues by Western blot (A) and real-time PCR (B), respectively. *P < 0.05, ** P < 0.01, *** P < 0.001. (C) Expression of
AEG-1 protein in each of the primary SGC tissues (T) and adjacent non-cancerous tissues (N) in the same patient determined by Western blot.
(D) Real time-PCR analysis of AEG-1 expression in each of the T and N tissues. GAPDH was used as an internal control. Columns, mean from
three parallel experiments; bars, SD. (E) Expression of AEG-1 mRNA in each of the primary SGC tissues (lower panel) and adjacent non-cancerous
tissues (upper panel) paired from the same patient determined by IHC.
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of patients with SGC
Spearman correlation analysis revealed that higher AEG-
1 protein levels were associated with shorter survival
times (P < 0.001), with a correlation coefficient of
-0.383. Kaplan-Meier analysis displayed that patients
with low AEG-1 expression had longer survival times,
whereas those with high AEG-1 expression had shorter
survival times (Figure 3, log-rank, P = 0.001). The
cumulative 5-year survival rate was 78.4% (95% confi-
dence interval, 0.665-0.903) in the low AEG-1 group,
compared to only 45.0% (95% confidence interval,
0.303-0.597) in the high AEG-1 group. In addition, mul-
tivariate Cox regression analysis revealed that clinical
stage, N classification and AEG-1 expression were inde-
pendent prognostic marker for SGC (Table 4).
Moreover, the prognostic value of AEG-1 expression
was analyzed when stratifying the patients according to
the clinical stage, T classification, N classification and M
classification. Because only nine samples in subgroups
N1-2 exhibited low AEG-1 expression, the overall survi-
val was not analyzed by stratification of N classification.
As shown in Figure 4, expression of AEG-1 was strongly
associated with overall survival of patients in the late
clinical stages. That is, patients with tumors exhibiting
high AEG-1 expression had clearly poor survival com-
pared with patients with low AEG-1 expression in the
clinical stage III-IV subgroup (Figure 4B, log-rank test,
P = 0.001). However, in the clinical stage I-II subgroup,
no significant difference was found between patients
with low and high AEG-1 expression (Figure 4A, log-
rank test, P = 0.474). Similarly, evidently shorter overall
survival time of patients with high AEG-1 expression
was revealed in the T3-4 subgroups (Figure 4D, log-rank
test, P = 0.008), but not in the T1-2 subgroups (Figure
4C, log-rank test, P = 0.171). Additionally, shorter over-
all survival time with high AEG-1 expression was
revealed in patients with distant metastasis (Figure 4F,
log-rank test, P = 0.017), while no such differences was
found in patients without distant metastasis (Figure 4E,
log-rank test, P = 0.138). Thus, AEG-1 seems to be a
valuable prognostic marker for patients with late stage
or aggressive SGC.
Discussion
In this study, we presented the first evidence of AEG-1
up-regulation in SGC biopsies at both the mRNA and
protein levels compared with adjacent non-cancerous
tissues. We also examined 141 SGC that covered a wide
spectrum of histological types. AEG-1 protein was
observed in 96.5% of archived SGC specimens, and the
expression level of AEG-1 protein was found to be sig-
nificantly correlated with advanced tumor stage and
TNM classification, as well as unfavorable prognosis of
Figure 2 AEG-1 protein overexpression in archived paraffin-embedded SGC tissue sections as examined by IHC. (A) Representative
images from IHC analyses of AEG-1 expression in seven histological types of SGC. (B) Representative images from IHC analyses of AEG-1
expression in normal human salivary gland tissues and primary SGC specimens. (C) Statistical analyses of the average MOD of AEG-1 staining
between normal salivary gland tissues (2 cases) and SGC specimens of different clinical stages. * P < 0.05.
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for AEG-1 protein in the development and progression
of SGC.
Due to the rarity and complexity of this type of can-
cer, it has been difficult to make clinical judgments
regarding diagnosis and treatment, as well as the prog-
nosis [1,4,5]. Meanwhile, little is known about its patho-
genesis, and few reliable prognostic markers have been
identified to predict aggressive biological behavior of
SGC. In early studies, HER-2 was found to be an
independent marker of poor prognosis of SGC [26,27].
HER-2/neu was found to be amplified and overex-
pressed in mucoepidermoid carcinomas, as markers of
poor prognosis independent of histopathologic grade,
tumor size and involvement of regional lymph nodes
[27]. The mutated p53 was also shown to be expressed
in 7 of 63 (11%) primary SGC in one report [28]. In
another study, patients with parotid gland cancer, mod-
erate and high expression of mutated p53 protein were
associated more frequently with metastases and poor
survival [29]. Other studies also showed that ras-p21
[30] and cyclin D1 [31] are overexpressed in a small
subset of SGC, while C-kit is up-regulated in a large
percentage of SGC [32,33]. Moreover, vascular endothe-
lial growth factor (VEGF) was found to be up-regulated
in 62% of SGC tissues, and its expression is significantly
correlated with lymph node metastasis, clinical stage
and disease-specific survival [34]. In a previous study,
we had found that sphingosine kinase 1 (SPHK1) was
associated with SGC progression [35]. In this study, we
Table 2 Correlation between AEG-1 expression and clinicopathologic characteristics of SGC
Characteristics AEG-1 expression Chi-square test P-value
Low or none No. cases (%) High
No. cases (%)
Gender Male 42 (29.79) 37 (26.24) 0.160
Female 20 (14.18) 42 (29.79)
Age (years) < 48 32 (22.70) 40 (28.37) 0.908
≥ 48 30 (21.28) 39 (27.66)
Clinical Stage I 10 (7.09) 6 (4.26) 0.001
II 28 (19.86) 21 (16.31)
III 13 (9.22) 21 (14.89)
IV 11 (7.80) 31 (21.99)
T classification T1 10 (7.09) 7 (4.96) 0.008
T2 31 (21.99) 29 (20.57)
T3 13 (9.22) 20 (14.18)
T4 8 (5.67) 23 (16.31)
N classification N0 53 (37.59) 53 (37.59) 0.008
N1 6 (4.26) 11 (7.80)
N2 3 (2.13) 15 (10.64)
M classification No 51 (36.17) 48 (34.04) 0.006
Yes 11 (7.8) 31 (21.99)
Histological Types Mucoepidermoid carcinoma 13 (9.22) 21 (14.89) 0.48
Adenoid cystic carcinoma 10 (7.09) 10 (7.09)
Acinar cell carcinoma 9 (6.38) 12 (8.51)
Adenocarcinoma 8 (5.67) 15 (10.64)
Squamous cell carcinoma 6 (4.26) 6 (4.26)
Salivary duct carcinoma 10 (7.09) 6 (4.26)
Basal cell carcinoma 6 (4.26) 9 (6.38)
Drinking No 55(39.01) 62 (43.97) 0.110
Yes 7(4.96) 17 (12.06)
Smoking No 48 (34.04) 53 (37.59) 0.178
Yes 14 (9.93) 26 (18.44)
Table 3 Spearman correlation analysis between AEG-1
and clinical pathologic factors
Variables AEG-1 expression level
Correlation coefficient P-value
Clinical staging 0.283 0.001
T classification 0.226 0.007
N classification 0.222 0.008
M classification 0.233 0.005
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prognosis and reduced survival of patients with SGC.
Multivariate analysis showed that AEG-1 protein levels
could be used as an independent prognostic predictor
for SGC patients, especially in subgroups with advanced
clinical stages (III-IV), higher T classification (T3-4),
and involvement of distant metastasis (M1). Thus, test-
ing the AEG-1 protein level may be useful for formulat-
ing prognosis and guiding the follow-up schedule in
SGC patients with advanced and aggressive SGC.
Figure 3 Kaplan-Meier curves with univariate analyses (log-rank) for patients with low AEG-1 expression (bold line) versus high AEG-1
expression tumors (dotted line). The cumulative 5-year survival rate was 78.4% in the low AEG-1 protein expression group (n = 62), whereas it
was only 45.0% in the high AEG-1 expression group (n = 79).
Table 4 Univariate and multivariate analyses of various prognostic parameters in patients with SGC Cox-regression
analysis
Univariate analysis Multivariate analysis
No.
patients
P Regression coefficient (SE) P Relative
risk
95% confidence interval
N classification < 0.001 1.319 (0.174) < 0.001 1.814 1.471-3.283
N0 106
N1 17
N2 18
Clinical staging < 0.001 1.189 (0.197) < 0.001 2.210 1.454-3.531
I1 6
II 49
III 34
IV 42
Expression of AEG-1 0.001 1.047 (0.325) 0.011 2.173 1.231-4.831
Low expression 62
High expression 79
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Page 7 of 10Figure 4 Overall survival curves stratified by AEG-1 levels according to clinical stage, T and M classifications. (A, B) The differences of
survival curves according to AEG-1 expression were seen in advanced clinical stage (B), but not in early clinical stage (A). (C, D) In the T3-T4
subgroup, patients with low AEG-1 expression showed significantly better overall survival (D). In the T1-T2 subgroup, the patients’ overall survival
times were not significantly different between the two groups (C). (E, F) Survival time was longer in patients with low AEG-1 expression regardless
of distant metastasis (F). No significant difference between low and high AEG-1 expression groups were found in the M0 subgroup (E).
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In this study, we found that up-regulation of AEG-1 corre-
lated with poor prognosis and reduced survival of patients
with SGC. Multivariate analysis showed that AEG-1 pro-
tein levels could be used as an independent prognostic
predictor for SGC patients, especially in subgroups with
advanced clinical stages (III-IV), higher T classification
(T3-4), and involvement of distant metastasis (M1). Thus,
testing the AEG-1 protein level may be useful for formu-
lating prognosis and guiding the follow-up schedule in
SGC patients with advanced and aggressive SGC.
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